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Cardiac Magnetic Resonance Detection of
Myocardial Scarring in Hypertrophic Cardiomyopathy
Correlation With Histopathology
and Prevalence of Ventricular Tachycardia
Deborah H. Kwon, MD,* Nicholas G. Smedira, MD,* E. Rene Rodriguez, MD,† Carmela Tan, MD,†
Randolph Setser, PHD,‡ Maran Thamilarasan, MD,* Bruce W. Lytle, MD,* Harry M. Lever, MD,*
Milind Y. Desai, MD*‡
Cleveland, Ohio
Objectives In hypertrophic cardiomyopathy (HCM) patients undergoing surgical myectomy, we sought to determine the as-
sociation between pre-operative cardiac magnetic resonance (CMR) findings, small intramural coronary arteriole
dysplasia (SICAD) on histopathology, and ventricular tachycardia (VT).
Background Myocardial scarring (fibrosis) and SICAD are frequently observed on histopathology in HCM patients. CMR mea-
sures wall thickness and detects scar.
Methods Sixty symptomatic HCM patients (62% men; mean age 51  14 years), with preserved ejection fraction (mean
64  5%) and no angiographic coronary disease underwent CMR (cine and delayed post-contrast) using a Sie-
mens 1.5 T scanner, followed by septal myectomy. Maximal basal septal thickness was recorded on cine CMR.
Scar was determined (percentage of total myocardium) on delayed post-contrast CMR images and quantified as
none, mild (0% to 25%), moderate (26% to 50%), or severe (50%). VT was assessed using Holter monitoring.
Degree of SICAD was determined (normal, mild, moderate, and severe) on histopathology of surgical specimen.
Results SICAD and scar were seen in 45 (75%) and 38 (63%) patients, respectively. In 15 patients without SICAD, 12
(80%) had no scar; 23 (70%) patients with mild SICAD had mild scar on CMR. On multivariate analysis, degree
of SICAD was independently associated with scar on CMR (Wald chi-square statistic: 6.8, p  0.01). Patients
with basal septal scar on CMR had higher VT frequency compared with those without (27% vs. 5%, p  0.03).
Conclusions A strong association exists between degree of SICAD and myocardial scarring seen on CMR. (J Am Coll Cardiol
2009;54:242–9) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.04.026M
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sultiple post-mortem studies have documented myocardial
brosis (interstitial or replacement) in hypertrophic cardio-
yopathy (HCM) patients that is distinct from the pattern
bserved in coronary artery disease (CAD) or patients with
ilated cardiomyopathy (1,2). With the recent emergence of
ardiac magnetic resonance (CMR), including delayed hy-
erenhancement magnetic resonance imaging (DHE-
RI), it is now possible to accurately detect areas of
yocardial fibrosis/scarring in vivo with a high degree of
ensitivity (3–5). Areas of delayed hyperenhancement on
MR have been shown to correlate with histologically
roven myocardial scar (4,6).
rom the *Heart and Vascular Institute, †Department of Pathology, and ‡Imaging
nstitute, Cleveland Clinic, Cleveland, Ohio. The institution receives modest research
upport from Siemens Medical Solutions.C
Manuscript received December 27, 2008; revised manuscript received February 23,
009, accepted April 3, 2009.In HCM patients, scarring, detected in vivo on DHE-
RI (Fig. 1), has been correlated with wall thickness
7–9), regional function (8), and ventricular tachyar-
hythmias (10 –12). The etiology of myocardial scarring
n HCM patients is debated, and multiple potential
actors have been proposed, including left ventricular
LV) hypertrophy and dynamic left ventricular outflow
ract (LVOT) gradient, resulting in potential pressure
ecrosis causing small intramural coronary arteriole dys-
lasia (SICAD) (1). However, all such previous associa-
ions have been demonstrated in necropsy studies of
CM patients presenting with sudden cardiac death
SCD) (1,2) or patients who underwent cardiac trans-
lantation (6), raising a concern for a selection bias in
hat only a high-risk population was studied. We sought
o study the association between basal interventricular
eptal thickness, myocardial scarring (both detected by
MR), SICAD (demonstrated by histopathology), and
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July 14, 2009:242–9 Myocardial Scar and HCMentricular tachyarrhythmia in HCM patients who under-
ent surgical myectomy.
ethods
opulation. This was an observational study of 60 consec-
tive HCM patients with symptomatic LVOT obstruction,
reserved left ventricular ejection fraction (LVEF), and no
ngiographic CAD who underwent comprehensive clinical,
chocardiographic, CMR, and angiographic evaluation fol-
owed by surgical myectomy (generally within 30 days). These
atients were subsequently entered into a registry. HCM was
efined as hypertrophied and nondilated LV in absence of
nother cardiac or systemic disease that could result in a similar
agnitude of hypertrophy (13–15). All patients were symp-
omatic at the time of surgery (100% in New York Heart
ssociation functional class III) from LVOT obstruction at
aseline (resting or provokable LVOT gradient50 mm Hg),
espite treatment with maximally tolerated medications. Cri-
eria for study exclusion were: ejection fraction 55%, angio-
raphic obstructive CAD (30% in at least 1 epicardial
oronary artery), history of myocardial infarction, or the pres-
nce of pacemakers, defibrillators, or aneurysm clips precluding
MR. Pre-operative clinical, echocardiographic, CMR, and
ngiographic findings, along with post-operative surgical his-
opathology findings, were recorded from the electronic med-
cal record. The Social Security Death Index was queried, and
urvival was ascertained during follow-up. This retrospective
egistry is approved by the local institutional review board with
waiver of individual informed consent.
chocardiography. Transthoracic echocardiography was
erformed using commercially available HDI 5000 (Philips
edical Systems, Bothell, Washington) and Acuson Se-
uoia (Siemens Medical Solution USA, Malvern, Pennsyl-
ania) machines. Resting LVOT peak velocity was mea-
ured by continuous-wave Doppler echocardiography, and
esting LVOT pressure gradient was estimated by using a
Figure 1 Delayed Hyperenhancement Cardiac Magnetic Resona
Delayed hyperenhancement magnetic resonance image in a patient with symptom
in the basal interventricular septum (arrow). Notice also the areas of patchy scarr
on the right is a 3-chamber view. LV  left ventricle.implified Bernoulli equation
16). Care was taken to avoid
ontamination of the LVOT
aveform by the mitral regurgi-
ation jet (17). In patients with
esting LVOT gradients 30
m Hg, provocative maneuvers,
ncluding Valsalva and amyl ni-
rite were also used to measure a
rovokable LVOT gradient.
aximal LVOT gradient was
efined as the highest recorded
VOT gradient (resting or pro-
okable) in a patient.
olter monitoring. The sub-
ects had pre-operative arrhyth-
ia monitoring performed using
48-h Holter monitor as part of
heir clinical workup. Presence of
entricular tachycardia (VT)
sustained or nonsustained), de-
ned as 3 or more consecutive
entricular beats at a rate 120
eats/min, was documented (18).
MR. The CMR examinations
ere performed on 1.5 T MR
canners (Siemens Medical Solu-
ions, Erlangen, Germany), ei-
her Sonata (40 mT/m maximum gradient strength, 200
/m/s maximum slew rate) or Avanto (45 mT/m maximum
radient strength, 200 T/m/s maximum slew rate), using
lectrocardiographic gating. Scout images were acquired
nitially to identify the cardiac axes. Subsequently, balanced
teady-state free precession images were acquired: echo time
TE)  1.6 ms, repetition time (TR)  3.3 ms, flip angle 
0°, temporal resolution  68 ms, and slice thickness  6
Images in a Patient With Hypertrophic Cardiomyopathy
pertrophic obstructive cardiomyopathy demonstrating areas of extensive scarring
the posterior wall (arrow). The image on the left is a short-axis view and image
Abbreviations
and Acronyms
CAD  coronary artery
disease
CI  confidence interval
CMR  cardiac magnetic
resonance
DHE-MRI  delayed
hyperenhancement
magnetic resonance
imaging
HCM  hypertrophic
cardiomyopathy
LV  left
ventricle/ventricular
LVEF  left ventricular
ejection fraction
LVOT  left ventricular
outflow tract
ROC  receiver-operating
characteristic
SCD  sudden cardiac
death
SICAD  small intramural
coronary arteriole dysplasia
VT  ventricular
tachycardiance
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Myocardial Scar and HCM July 14, 2009:242–9m (long-axis images) or 8 to 10 mm (contiguous short-
xis images encompassing the entire LV volume, from apex
o base). For short-axis images, the matrix size varied from
40 to 180 in the x-direction (phase-encoding direction)
nd 256 in the y-direction. In long-axis images, the matrix
ize varied from 120 to 210 in the x-direction (phase-
ncoding direction) and 256 in the y-direction. For patients
ble to suspend respiration, breath-hold duration was 10 to
5 s, depending on the heart rate; otherwise, images were
cquired using 3 signal averages. Subsequently, DHE-MRI
mages were obtained in the same long- and short-axis
rientations as in the above-described balanced steady-state
ree precession images, 20 min after injection of 0.2
mol/kg of gadolinium dimenglumine (Magnevist, Berlex
maging, Wayne, New Jersey), using a phase-sensitive
nversion recovery spoiled gradient echo sequence (19): TE
4 ms, TR  8 ms, flip angle  30°, bandwidth  140
z/pixel, 23 k-space lines acquired every other RR-interval,
eld of view (varied from 228 to 330 in the x-direction and
60 to 330 in the y-direction), and matrix size (varied from
40 to 180 in the x-direction and 256 in the y-direction).
his gave a spatial resolution of 1.5 to 2.1 mm (x-direction)
y 1.1 to 1.4 mm (y-direction).
LVEF and end-diastolic basal interventricular septal
hickness were measured by standard off-line analysis of
hort-axis cine images, using Argus analytical software
Siemens Medical Solutions). The presence and amount of
car was assessed using phase-sensitive DHE-MRI (Fig. 1),
valuating only the anteroseptum at the basal and mid-
entricular levels to approximately correspond with the area
emoved on myectomy (as illustrated in Fig. 2). For quan-
itation of scar, inner and outer myocardial edges were
anually delineated. Scar was determined semiautomati-
ally (as a percentage of total myocardium) using a viability
rototype software (Siemens Medical Solutions, Erlangen,
ermany) and defined as having an intensity2 SDs above
ormal myocardium (identified using a user-specified region
f interest) (20,21). Any areas that were identified as scar by
he software, but not deemed to be scar by the user, were
xcluded manually by the user. Such quantitative scar
nalysis has been shown to be highly reproducible in a
revious study (20). The degree of scar was subsequently
raded as follows: none, mild (1% to 25%), moderate (26%
o 50%), and severe (50%), as described in previous
HE-MRI studies (22,23). CMR assessment was blinded
rom all other analyses.
yectomy. All patients underwent surgical myectomy
ithout coronary revascularization using techniques as pre-
iously described (Fig. 2) (24,25).
istopathology. All specimens were fixed in 10% formalin
nd grossly examined by the cardiovascular pathology staff
E.R.R. and C.T.). Particular attention was placed in
ectioning along longitudinally oriented fascicles of muscle
uring gross evaluation to allow for better assessment of
yocyte disarray in the microscopic examination. Thendocardium was always examined, and sections perpendic- tlar to areas of thickened endocardium were taken.
ormalin-fixed tissue was routinely processed for paraffin
mbedding. Sections were stained with hematoxylin-eosin
nd Movat pentachrome stains. Histologic sections were
valuated for the presence of myocyte disarray, fibrosis, and
ICAD. SICAD was defined by the presence of intimal
nd/or medial thickening with smooth muscle proliferation
nd disorganization (Fig. 3). The severity of SICAD was
ssessed based on the frequency that abnormal vessels were
ound and graded semiquantitatively as follows: absent
none to only a single affected artery), mild (1% to 25% of
rteries affected), moderate (26% to 50%), and severe
50%). This grading has been adapted at our institution,
ased upon previous work (1,2). Similarly, degree of myo-
ardial fibrosis was assessed as normal, mild, moderate, and
evere, as previously described (1). Histopathologic analysis
as blinded from all other analyses.
tatistics. Baseline demographics, risk factors, and clinical
ariables are descriptively summarized. Continuous vari-
bles are expressed as mean  SD and/or median. Cate-
orical data are presented as percentage frequency. Differ-
nces between groups were compared with the use of the
tudent t test or analysis of variance (for parametric vari-
bles) and Mann-Whitney test (for nonparametric vari-
bles) for continuous variables. The chi-square test was used
or categorical variables. The Pearson correlation coefficient
ethod was utilized to test for association between contin-
ous variables. Receiver-operator characteristic (ROC)
urve analysis was performed to discriminate between pa-
Figure 2 Schematic Representation of the Portion
of Basal Septum Removed During Myectomy
Schematic illustration of the basal interventricular septum removed during sur-
gical myectomy (area within the dotted line) in a hypertrophic cardiomyopathy
patient with symptomatic left ventricular outflow tract obstruction. AO  aorta;
AV  aortic valve; IVS  interventricular septum; LA  left atrium; LV  left
ventricle; MV  mitral valve; PM  papillary muscles.ients with or without SICAD, based upon the degree of
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July 14, 2009:242–9 Myocardial Scar and HCMasal septal hypertrophy. An area under the curve with a
5% confidence interval (CI) was calculated. A cutoff with
est sensitivity and specificity is reported. Univariate and
orward stepwise multivariate logistic regression analyses
ere performed to test the association between dependent
nd multiple independent variables. For multivariate anal-
sis, only those variables with a p value 0.1 on univariate
nalysis were entered into the model. Data assembly and
asic statistical comparisons were performed with JMP
oftware version 6.0.2 (SAS Institute, Cary, North Caro-
ina). Advanced statistical analysis was performed using
PSS version 11 (SPSS Inc., Chicago, Illinois). A p value
0.05 was considered significant.
esults
he baseline data of the entire study population is shown in
able 1. There have been no deaths or cardiac transplanta-
Figure 3 Small Intramural Dysplastic Coronary Arteriole in a Pa
Histopathologic analysis of the basal septal specimen removed during surgical my
mural coronary arteries with narrowed lumen due to disordered medial smooth mu
lagen deposition. Scarring is also present in the media and adventitia (Movat pent
haracteristics of the Study PopulationTable 1 Characteristics of the Study Population
Tota
(
Women 2
Age, yrs 51 1
History of hypertension 1
History of syncope 1
Beta-blocker use 4
Family history of HCM
Mean LVEF 6
Mean resting LVOT gradient, mm Hg 58
Mean maximal (resting or provokable) LVOT gradient, mm Hg 110
Mean basal interventricular septal thickness on CMR, cm 2.1
Presence of basal septal scar on CMR 3
Amount of basal septal scar (as % of normal
basal septal myocardium) on CMR
10
7.4%
Frequency of myocyte disarray 4
alues are n (%), mean  SD (range) median, mean  SD (range), or median (range). p values a
CMR  cardiac magnetic resonance; HCM  hypertrophic cardiomyopathy; LVEF  left ventricular eje
ysplasia.ion in the follow-up period (308 180 days) in this group.
f the study group, 53 (88%) patients had Holter monitor-
ng, of which 10 (19%) had VT. Only 2 patients had an
utomated implantable defibrillator placed during the
ollow-up period.
istopathologic data. In the study group, 15 (25%) pa-
ients had no SICAD, 33 (55%) had mild, 10 (17%) had
oderate, and 2 (3%) had severe SICAD. Based upon the
resence or absence of SICAD, patients were divided into 2
roups: group A: SICAD (n 45) and group B: no SICAD
n  15); and the characteristics of these groups are shown
n Table 1. Also, the classification based on fibrosis on
istopathology was as follows: 19 (32%) patients with a
ormal pattern of fibrosis, 33 (55%) with mild, and 8 (13%)
ith moderate fibrosis.
maging data versus histopathology. As demonstrated in
able 1, the mean LVEF and LVOT gradients (both
With Hypertrophic Cardiomyopathy
y of a patient with hypertrophic obstructive cardiomyopathy. (A) Dysplastic intra-
yperplasia or (B) intimal hyperplasia with increased mucopolysaccharide and col-
e stain, 200).
lation
0)
Group A
SICAD Present
(n  45)
Group B
SICAD Absent
(n  15) p Value
%) 18 (40%) 5 (33%) 0.6
–76), 49 50 14 (18–76), 49 51 15 (25–74), 53 0.8
%) 8 (18%) 6 (40%) 0.1
%) 8 (18%) 3 (20%) 0.8
%) 37 (82%) 12 (80%) 0.8
%) 9 (20%) 0 (0%) 0.02
% 64 5% 64 9% 0.9
–196) 60 46 (8–196) 54 41 (10–143) 0.7
4–209) 111 39 (54–209) 108 31 (62–185) 0.8
.6 2.3 0.7 1.7 0.3 0.005
%) 35 (78%) 3 (20%) 0.001
1.4%
54%)
12.3 12%
7.4% (0%–54%)
3.1 8%
0% (0%–27%)
0.005
%) 38 (84%) 7 (47%) 0.003
e difference between groups A and B.tient
ectom
scle h
achroml Popu
n  6
3 (38
4 (18
4 (23
1 (18
9 (82
9 (15
4 5
44 (8
37 (5
3 0
8 (63
.2 1
(0%–
5 (75
re for th
ction fraction; LVOT  left ventricular outflow tract; SICAD  small intramural coronary arteriole
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Myocardial Scar and HCM July 14, 2009:242–9esting as well as provokable) were similar in groups A and
. However, basal interventricular septal thickness on CMR
as significantly higher in group A compared with group B.
edian basal interventricular septal thickness in the patient
opulation was 1.9 cm (range 1.5 to 3.9 cm). On ROC
urve analysis, basal interventricular septal thickness had a
ignificant association with presence or absence of SICAD
area under the curve  0.76, p  0.001, 95% CI: 0.62 to
.88). For our population, based on ROC curve analysis, at
basal interventricular septal thickness cutoff of 1.95 cm,
he sensitivity and specificity for predicting the presence of
ICAD were 58% and 80%, respectively.
The distribution of basal interventricular septal scarring
n DHE-MRI was as follows: none (22, or 37%), mild (33,
r 55%), moderate (4, or 7%), and severe (1, or 2%). On
hi-square testing, there was a strong association between
egree of scarring noted on DHE-MRI, and fibrosis re-
orted on histopathology (p  0.001), as follows. Of the 22
atients with no scar on DHE-MRI, 19 had normal fibrosis
eported on histopathology. Similarly, 33 patients had
vidence of mild fibrosis (on histopathology) and scar (on
HE-MRI). There was a weak correlation between basal
nterventricular septal thickness and scar percentage, mea-
ured on CMR (r  0.30, p  0.02). The distribution of
atients, based upon presence or absence of scar on DHE-
RI is shown in Table 2. As demonstrated in Table 2, the
ean basal interventricular septal thickness was significantly
igher in patients with DHE-MRI scarring compared with
hose without. Also, a greater percentage of patients with
carring seen on DHE-MRI had evidence of VT on Holter
onitoring (27% vs. 5%, p  0.03).
As shown in Table 1, a greater percentage of patients
ith SICAD had evidence of myocardial scarring on DHE-
RI as compared with those without SICAD. Figure 4
emonstrates the significant association between different
egrees of scarring, seen on DHE-MRI and SICAD. Of
he 15 patients without SICAD, 12 (80%) had no scar on
HE-MRI, whereas 23 (70%) with mild SICAD had
haracteristics of the Study Population, Based Upon Presence or ATable 2 Characteristics of the Study Population, Based Upon P
Sc
Women
Age, yrs 49
History of hypertension
History of syncope
Beta blocker use
Family history of HCM
Mean LVEF
Mean resting LVOT gradient, mm Hg
Mean maximal (resting or provokable) LVOT gradient, mm Hg 1
Mean basal interventricular septal thickness on CMR, cm
Presence of myocyte disarray
Presence of SICADalues are n (%), mean  SD (range) median, mean  SD, or mean  SD (range).
Abbreviations as in Table 1.vidence of mild scar. On ROC analysis, scar percentage on
HE-MRI was a significant predictor of the presence of
ICAD (area under the curve: 0.77, p  0.002, 95% CI:
.63 to 0.92). Subsequently, we performed univariate and
ultivariate logistic regression analysis to test the associa-
ion between myocardial scarring noted on DHE-MRI and
ultiple potential clinical and imaging variables. The results
re shown in Table 3. Based on the logistic regression
nalysis, the odds of having myocardial scarring on DHE-
RI was significantly higher in presence of SICAD (odds
atio [OR]: 14 [95% CI: 3 to 60], p  0.009), as compared
o septal thickness less than the median (OR: 6 [95% CI: 2
o 19], p  0.05).
iscussion
o the best of our knowledge, this is the first in vivo study
o demonstrate an independent association between pres-
Figure 4 Association Between Degree of
Myocardial Scarring on DHE-MRI and SICAD
Association between degree of myocardial scarring on delayed hyper-
enhancement cardiac magnetic resonance (DHE-MRI) and small intramural
coronary arteriole dysplasia (SICAD) in the study population.
ce of Scar on CMRnce or Absence of Scar on CMR
sent on CMR
 38)
Scar Absent on CMR
(n  22) p Value
(34%) 10 (45%) 0.4
(18–73), 49 53 16 (25–76), 55 0.3
(16%) 8 (36%) 0.07
(16%) 5 (23%) 0.5
(82%) 18 (82%) 0.9
(21%) 1 (5%) 0.062
 3% 65 4% 0.2
7 (8–196) 56 40 (11–149) 0.7
0 (60–209) 110 30 (8–196) 0.9
 0.7 1.8 0.2 0.008
(79%) 15 (68%) 0.4
(92%) 10 (45%) 0.001bsenrese
ar Pre
(n
13
 13
6
6
31
8
64
60 4
10 4
2.3
30
35
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July 14, 2009:242–9 Myocardial Scar and HCMnce (and degree) of SICAD by histopathology and myo-
ardial scarring detected by DHE-MRI in a series of HCM
atients. We demonstrate, using CMR, that there is a
ignificant association between maximal basal interventric-
lar thickness, myocardial scarring (both evaluated by
MR), and SICAD (described on histopathology) in the
yectomy specimen that is removed at surgery in HCM
atients who underwent surgical myectomy for symptomatic
VOT obstruction. No patient had evidence of significant
picardial CAD on pre-operative angiography, and all
atients had preserved LVEF. We further demonstrate that
he association between degree of SICAD and presence of
HE-MRI scarring was independent of other factors in-
luding age, sex, hypertension, LVOT gradient, and myo-
yte disarray. It also appears that the association of DHE-
RI scarring with SICAD is much stronger than with basal
eptal thickness. Previous studies have performed quantita-
ive/semiquantitative analysis of the degree of SICAD and
car in a necropsy setting on the entire heart (2). However,
n our study, only basal septal tissue removed during
yectomy was available. Thus, a semiquantitative estima-
ion of scar and SICAD (as percentage of the myocardial
ortion removed at myectomy) was performed.
The scar assessment and quantification was performed in
semiautomatic fashion using DHE-MRI. For the purpose
f this study, we specifically recorded the presence of
HE-MRI scar in the basal anteroseptum at the basal and
id-ventricular levels to approximately correspond with the
rea removed on myectomy (Fig. 2). With the recent
mergence of DHE-MRI, it is now possible to precisely
etect areas of myocardial fibrosis/scarring in vivo with a
igh degree of sensitivity (3–5). Areas of delayed hyper-
nhancement have been shown to correlate with histologi-
ally proven myocardial scar (4,6). Hence, we can have a
etailed “in vivo” evaluation of myocardial scarring, which,
n the past was only done in histopathologic specimens.
As demonstrated in recent studies (10–12), there was a
ignificant association between scarring seen on DHE-MRI
nivariate and Multivariate Logistic Regression Analysis Testinghe Associ tion Be ween My cardial Scarring and Various ParametTable 3 Univariat and Multivariate Logistic Regression A alysthe Association Between Myocardial Scarring and Vari
Univaria
Wald Chi-Square Stati
Degree of SICAD on histopathology 10.8
Basal interventricular septal thickness on CMR 8.5
Hypertension 3.2
Family history of HCM 2.5
Age (yrs) 1.1
Sex (male) 0.7
Syncope 0.4
Beta-blocker 0.001
Resting LVOT gradient 0.13
Maximal (resting or provokable) LVOT gradient 0.003
LVEF 1.8
Myocardial disarray on histopathology 0.85bbreviations as in Table 1.nd occurrence of VT. However, longer-term follow-up
ata will be required to conclusively demonstrate the asso-
iation between SICAD, scarring, and increased risk for
udden death (not just VT). Previous observations demon-
trating the association between scarring and SICAD were
erived from autopsy studies of HCM patients who died
uddenly (1,2). These studies have the potential for a
election bias as only a high-risk sudden-death phenotype
as studied.
Previous histopathologic studies have reported an in-
reased frequency of SICAD, particularly in the interven-
ricular septum, in HCM patients (1). That study also
uggested that besides increased intramyocardial wall ten-
ion, there are other potential factors in the pathogenesis of
ICAD, including the underlying cardiomyopathy itself (1).
he observation of a strong association between SICAD
nd increased septal thickness suggests that these findings
ay occur later in the HCM disease process. Another
ssociation that needs further exploration is that between
ICAD and genetics. Indeed, in the current study, signif-
cantly more patients with SICAD had a positive family
istory of HCM, compared to those without SICAD.
rrespective of the etiology and duration, it is well docu-
ented using CMR and positron emission tomography that
CM patients have evidence of microvascular dysfunction
26,27). In a CMR study of 35 HCM patients with a mean
VEF of 74  9%, the authors demonstrated that the
esting myocardial blood flow was similar to controls;
owever, following vasodilator challenge, the hyperemic
lood flow was substantially lower in HCM patients (27).
hus, it is conceivable that HCM patients with SICAD
ave microvascular dysfunction resulting in repeated epi-
odes of ischemia leading to myocardial scarring. Based on
he current study, it appears that SICAD can be seen in
CM patients even when the basal septum is 2 cm in
hickness.
Aside from ischemia, there could be other potential reasons
or development of myocardial scarring in HCM. Although
sting
arameters
lysis Multivariate Analysis
p Value Wald Chi-Square Statistic p Value
0.001 6.8 0.009
0.004 3.8 0.05
0.07 1.1 0.3
0.1 0.18 0.7
0.3 N/A
0.4 N/A
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Myocardial Scar and HCM July 14, 2009:242–9CM is caused by mutation in genes encoding sarcomere
omponents, an important component of its phenotypic ex-
ression is associated with increased myocardial connective
issue, a principal component of which is collagen (28,29).
ifferent patterns of scarring have been observed (30). There
ay be a generalized increase in the normal structural skeletal
ramework of the myocardium, or in extreme cases, individual
yocytes may become encased in collagen. Myocardial scar-
ing in HCM has been demonstrated in minimally symptom-
tic individuals, patients with increased frequency of ventricular
rrhythmias, and individuals at high risk of sudden death or
yocardial thinning and dilation (8–12).
linical implications. In light of the associations demon-
trated in the current study, it could be potentially important to
ssess whether HCM patients with SICAD (and scar) have
ong-term worse outcomes compared to those without. Also,
n light of emerging associations between myocardial scarring
nd VT in HCM patients, we likely need to evaluate the
ontinued role of beta-blockers following the surgical relief of
VOT obstruction. An interesting study would be to prospec-
ively evaluate the impact of continued beta-blocker use on
utcomes in HCM patients with significant myocardial scar-
ing (assuming a high prevalence of coronary dysplasia) follow-
ng surgical relief of LVOT obstruction.
tudy strengths and limitations. The study is limited by a
mall sample size. There is a selection bias because our
atient population consisted of HCM patients deemed
ymptomatic due to LVOT obstruction who underwent
eptal myectomy. Also, only those patients who were able to
ndergo CMR were included in the study. However, unlike
revious autopsy reports, this is a relatively lower-risk HCM
opulation, as no patients had SCD or LV systolic dysfunc-
ion. Also, the majority of patients in the current study
opulation had mild scarring and mild SICAD. We do not
ave data on stress CMR to demonstrate that these patients
ndeed had functionally significant microvascular dysfunc-
ion. Because of the relatively small sample size, there is
otential for over-fitting in statistical analysis. The current
bservational study only tests associations and does not
rove causality. However, scar assessment by DHE-MRI
an be considered a form of in vivo histologic assessment,
ith the additional advantage that it can be performed in
atients with any HCM phenotype with global myocardial
overage with a potential to serially monitor disease
rogression.
onclusions
CM patients with no epicardial CAD and preserved
VEF, undergoing myectomy due to symptomatic LVOT
bstruction, have an increased frequency of histopatholog-
cally proven SICAD and myocardial scarring (seen on
HE-MRI) in the interventricular septum. There is a
trong association between degree of SICAD and myocar-
ial scarring, independent of age, sex, risk factors, and
VOT gradient. Although myocardial scarring is associatedith VT, longer-term longitudinal studies are required to
onclusively ascertain the association between scarring and
udden death.
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